Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
roche
6
×
san francisco blog main
san francisco top stories
6
×
boston blog main
boston top stories
clinical trials
biotech
cancer
blueprint medicines
deals
fda
indiana blog main
indiana top stories
investing
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
avapritinib
boston
boulder/denver blog main
boulder/denver top stories
cancer drugs
detroit blog main
detroit top stories
drugs
eli lilly
What
cancer
6
×
drug
6
×
fda
medicines
approval
blueprint
genetic
ret
roundup
targets
address
advanced
ahead
ambien
american
annual
approved
approves
arrival
asco
attendees
attention
award
bio
biotech
camp’s
candidate
carries
cash
certain
chicago
city
clinical
combinations
community’s
currently
data
days
death
decades
Language
unset
Current search:
cancer
×
drug
×
" san francisco top stories "
×
roche
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More